首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
【24h】

Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques

机译:使用两种不同的注射技术对incobotulinumtoxinA在咬肌治疗中的前瞻性评估

获取原文
           

摘要

Background: IncobotulinumtoxinA (Xeomin Cosmetic?) has been used previously in the management of masseteric hypertrophy. However, a standardized injection technique has not been established. The goal of the present study was to evaluate the efficacy and safety of two injection techniques in the management of masseteric hypertrophy using incobotulinumtoxinA. Methods: Thirty female patients with masseteric hypertrophy were recruited and evenly randomized to receive bilateral treatments of either a single-injection technique (SIT) or a multiinjection technique (MIT). Improvement of masseteric hypertrophy was assessed at week 16 using standardized measurements and photographs. Patients completed a 5-point satisfaction questionnaire while physicians completed the Global Aesthetic Improvement Scale (GAIS) and 10-point photonumeric masseter prominence rating scale. Results: There were no significant differences in physician ratings on the photonumeric scale and GAIS between the SIT and MIT groups. Results of the standardized measurements also revealed no significant difference between injection techniques. Majority of patients at every visit reported being “satisfied” with treatment results. Clinically, the number and severity of adverse events were similar between groups. Conclusion: This study supports the noninferiority of both SIT and MIT with regard to efficacy and safety in the management of masseteric hypertrophy, using incobotulinumtoxinA.
机译:背景:IncobotulinumtoxinA(Xeomin Cosmetic?)先前已用于治疗咬肌肥大。但是,尚未建立标准化的注射技术。本研究的目的是评估两种注射技术在使用incobotulinumtoxinA治疗咬肌肥大中的有效性和安全性。方法:招募了30例女性肥大性肥大患者,并将其随机分为单次注射技术(SIT)或多次注射技术(MIT)的双侧治疗。使用标准的测量和照片在第16周评估了咬肌肥大的改善。患者填写了5点满意度问卷,而医生则填写了全球审美改善量表(GAIS)和10点光数字咬肌突出评定量表。结果:SIT组和MIT组在光数字量表和GAIS上的医师评分没有显着差异。标准化测量的结果还表明,注射技术之间没有显着差异。多数患者每次就诊都对治疗结果表示“满意”。在临床上,两组之间不良事件的数量和严重程度相似。结论:本研究支持使用incobotulinumumxinA在治疗咬肌肥大方面的有效性和安全性在SIT和MIT方面均不逊色。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号